Mountaineer Biomarker Study: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HET2+ Metastatic Colorectal Cancer.

Administered By

Awarded By

Contributors

Start/End

  • April 7, 2020 - April 30, 2023